NO20041484L - Cisplatinformuleringer med redusert toksisitet og fremgangmater for anvendelse av disse - Google Patents

Cisplatinformuleringer med redusert toksisitet og fremgangmater for anvendelse av disse

Info

Publication number
NO20041484L
NO20041484L NO20041484A NO20041484A NO20041484L NO 20041484 L NO20041484 L NO 20041484L NO 20041484 A NO20041484 A NO 20041484A NO 20041484 A NO20041484 A NO 20041484A NO 20041484 L NO20041484 L NO 20041484L
Authority
NO
Norway
Prior art keywords
feedstock
reduced toxicity
cisplatin formulations
cisplatin
formulations
Prior art date
Application number
NO20041484A
Other languages
English (en)
Norwegian (no)
Inventor
Patrick Fogarty
Original Assignee
Tosk Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tosk Inc filed Critical Tosk Inc
Publication of NO20041484L publication Critical patent/NO20041484L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20041484A 2001-09-24 2004-04-13 Cisplatinformuleringer med redusert toksisitet og fremgangmater for anvendelse av disse NO20041484L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32456601P 2001-09-24 2001-09-24
PCT/US2002/029669 WO2003026570A2 (fr) 2001-09-24 2002-09-20 Formulations de cisplatine a toxicite reduite et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
NO20041484L true NO20041484L (no) 2004-04-13

Family

ID=23264163

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041484A NO20041484L (no) 2001-09-24 2004-04-13 Cisplatinformuleringer med redusert toksisitet og fremgangmater for anvendelse av disse

Country Status (18)

Country Link
US (1) US20040258771A1 (fr)
EP (1) EP1435963A4 (fr)
JP (1) JP2005510471A (fr)
KR (1) KR20040048900A (fr)
CN (2) CN1589149A (fr)
AU (1) AU2002334595B2 (fr)
BR (1) BR0212744A (fr)
CA (1) CA2461219A1 (fr)
EA (1) EA007481B1 (fr)
HU (1) HUP0500642A2 (fr)
IL (1) IL160960A0 (fr)
MX (1) MXPA04002707A (fr)
NO (1) NO20041484L (fr)
NZ (1) NZ531936A (fr)
PL (1) PL370867A1 (fr)
SK (1) SK1472004A3 (fr)
WO (1) WO2003026570A2 (fr)
ZA (1) ZA200402229B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815833B2 (en) 2006-11-09 2014-08-26 Seidose, LLC Stable amifostine liquid concentrate
UY30915A1 (es) * 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
US20100035853A1 (en) * 2008-08-07 2010-02-11 Hyogo College Of Medicine Method for preventing or treating cisplatin-induced nephrotoxicity
WO2011097480A1 (fr) * 2010-02-05 2011-08-11 University Of Louisville Research Foundation, Inc. Compositions exosomales et procédés pour le traitement de maladies
CN103044338B (zh) * 2012-12-12 2016-08-03 天津医科大学总医院 miR-21小分子抑制剂及应用
US11554138B2 (en) 2015-07-16 2023-01-17 The University Of Hong Kong Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy
EP3538074B1 (fr) * 2016-11-11 2023-07-26 Western University Of Health Sciences Méthodes de traitement de carcinomes urothéliaux de la voie excrétrice supérieure
CN112574255B (zh) * 2019-09-27 2024-05-10 中国科学院上海有机化学研究所 一类基于有机胂的cdk抑制剂及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
US4302446A (en) * 1979-10-02 1981-11-24 Bristol-Myers Company Pharmaceutical compositions
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5770576A (en) * 1989-08-30 1998-06-23 Cytran, Inc. Pharmaceutical dipeptide compositions and methods of use thereof: systemic toxicity
DE4024885C2 (de) * 1990-08-06 2002-07-18 Nattermann A & Cie Verwendung von 2-Phenyl-1,2-benzisoselenazol-3(2H)-on
US5366723A (en) * 1993-03-05 1994-11-22 Istvan Tulok Method of alleviating toxicity originating from treatment with anticancer platinum compounds
JPH06321792A (ja) * 1993-05-18 1994-11-22 Tsumura & Co 副作用軽減剤
US5646011A (en) * 1994-04-08 1997-07-08 Yokoyama; Shiro Cisplatin resistance gene and uses therefor
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5792748A (en) * 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US5922689A (en) * 1995-09-11 1999-07-13 Unitech Pharmaceuticals, Inc. Cisplatin analogs for cancer treatment
US6077545A (en) * 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
CA2265983C (fr) * 1996-10-03 2003-12-23 Kathleen C. M. Campbell Utilisation therapeutique de methionine d pour reduire la toxicite de composes antitumoraux contenant du platine
US6187817B1 (en) * 1996-10-03 2001-02-13 Southern Illinois University School Of Medicine Therapeutic use of d-methionine to reduce the toxicity of platinum-containing anti-tumor compounds
US6251355B1 (en) * 1996-12-25 2001-06-26 Nippon Kayaku Kabushiki Kaisha Fine cisplatin powder and process for the production thereof
US6030783A (en) * 1997-01-31 2000-02-29 Massachusetts Institute Of Technology Photo-potentiation of cisplatin chemotherapy
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6001817A (en) * 1998-01-12 1999-12-14 Unitech Pharmaceuticals, Inc. Pharmaceutical composition comprised of cisplatin, and processes for making and using same
US6074626A (en) * 1998-03-20 2000-06-13 Molecular Radiation Management, Inc. Radioactive cisplatin in the treatment of cancer
WO2000023074A1 (fr) * 1998-10-22 2000-04-27 Binex Co., Ltd. Composition pharmaceutique contenant de la decursine
US6130245A (en) * 1998-10-26 2000-10-10 Unitech Pharmaceuticals, Inc. Dinuclear platinum complexes as cisplatin analogs for cancer treatment
JP5409981B2 (ja) * 2000-05-15 2014-02-05 セルジーン コーポレイション 癌治療用の組成物および方法

Also Published As

Publication number Publication date
CN101062053A (zh) 2007-10-31
MXPA04002707A (es) 2005-06-06
WO2003026570A3 (fr) 2004-01-22
EP1435963A2 (fr) 2004-07-14
WO2003026570A2 (fr) 2003-04-03
AU2002334595B2 (en) 2007-03-01
SK1472004A3 (en) 2004-10-05
PL370867A1 (en) 2005-05-30
JP2005510471A (ja) 2005-04-21
US20040258771A1 (en) 2004-12-23
EA200400348A1 (ru) 2005-04-28
CA2461219A1 (fr) 2003-04-03
BR0212744A (pt) 2005-10-25
EP1435963A4 (fr) 2005-10-26
NZ531936A (en) 2006-10-27
ZA200402229B (en) 2005-03-22
HUP0500642A2 (hu) 2005-11-28
KR20040048900A (ko) 2004-06-10
EA007481B1 (ru) 2006-10-27
IL160960A0 (en) 2004-08-31
CN1589149A (zh) 2005-03-02

Similar Documents

Publication Publication Date Title
DK1329456T3 (da) Glucopyranosyloxybenzylbenzenderivater og medicinske sammensætninger indeholdende samme
NO2014027I1 (no) Aripiprazol (preparat - krav 1 og 2 i patentet)
NO20035366D0 (no) Benzoylsulfonamider og sulfonylbenzamidiner for anvendelse som antitumormidler
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
DE60218695D1 (de) Biosensoren und messverfahren
NO20040469L (no) Heterocykliske forbindelser samt fremstilling og anvendelse derav
NO20042147L (no) Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
DE60326611D1 (de) N und dergleichen
NO20053974D0 (no) Tienopyrimidinforbindelser og anvendelse derav.
AU2003284808A8 (en) The derivatives of pyridone and the use of them
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
GB2393963B (en) Sliding composition and sliding member
GB0220214D0 (en) Compounds and their use
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
NO20041484L (no) Cisplatinformuleringer med redusert toksisitet og fremgangmater for anvendelse av disse
DK1456377T3 (da) Syn3-sammensætninger og fremgangsmåder
GB0200721D0 (en) Toxicity test
GB0227906D0 (en) Compounds and their use
GB2373359B (en) Composition for use in the testing of smoke detectors
DK1680134T3 (da) Sammensætninger og anvendelser deraf
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
GB0218031D0 (en) Compounds and their use
GB0220215D0 (en) Compounds and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application